255 related articles for article (PubMed ID: 37467618)
1. Recent advance of small-molecule drugs for clinical treatment of osteoporosis: A review.
Zhang JY; Zhong YH; Chen LM; Zhuo XL; Zhao LJ; Wang YT
Eur J Med Chem; 2023 Nov; 259():115654. PubMed ID: 37467618
[TBL] [Abstract][Full Text] [Related]
2. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
3. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Reginster JY
Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
[TBL] [Abstract][Full Text] [Related]
4. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Ishtiaq S; Fogelman I; Hampson G
J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
[TBL] [Abstract][Full Text] [Related]
5. [[Antiresorptive agents in the treatment of osteoporosis].
Novak S
Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
[TBL] [Abstract][Full Text] [Related]
6. [Current topics in drug therapy aiming at bone resorption].
Yasui T; Tanaka S
Clin Calcium; 2006 Sep; 16(9):1475-79. PubMed ID: 16951471
[TBL] [Abstract][Full Text] [Related]
7. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.
Palacios S; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Tremollieres F; Vujovic S; Rees M; Rozenberg S
Maturitas; 2012 Feb; 71(2):194-8. PubMed ID: 22176952
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
[TBL] [Abstract][Full Text] [Related]
9. An overview of the management of osteoporosis in the aging female population.
Amin U; McPartland A; O'Sullivan M; Silke C
Womens Health (Lond); 2023; 19():17455057231176655. PubMed ID: 37218715
[TBL] [Abstract][Full Text] [Related]
10. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
Gorai I;
Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
[TBL] [Abstract][Full Text] [Related]
11. New management options for osteoporosis with emphasis on SERMs.
McClung MR
Climacteric; 2015; 18 Suppl 2():56-61. PubMed ID: 26503459
[TBL] [Abstract][Full Text] [Related]
12. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
Takada J; Iba K; Yamashita T; Yoshizaki T
Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365
[TBL] [Abstract][Full Text] [Related]
13. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
Epstein S
Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological diversity among drugs that inhibit bone resorption.
Russell RG
Curr Opin Pharmacol; 2015 Jun; 22():115-30. PubMed ID: 26048735
[TBL] [Abstract][Full Text] [Related]
15. Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis.
McClung MR
Bone; 1996 Nov; 19(5 Suppl):195S-198S. PubMed ID: 8922662
[TBL] [Abstract][Full Text] [Related]
16. Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene.
Ohta H; Uemura Y; Sone T; Tanaka S; Soen S; Mori S; Hagino H; Fukunaga M; Nakamura T; Orimo H; Shiraki M;
Calcif Tissue Int; 2023 Apr; 112(4):430-439. PubMed ID: 36707436
[TBL] [Abstract][Full Text] [Related]
17. Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis.
Reginster JY; Neuprez A; Beaudart C; Lecart MP; Sarlet N; Bernard D; Disteche S; Bruyere O
Drugs Aging; 2014 Jun; 31(6):413-24. PubMed ID: 24797286
[TBL] [Abstract][Full Text] [Related]
18. How to manage postmenopausal osteoporosis?
Body JJ
Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309
[TBL] [Abstract][Full Text] [Related]
19. Denosumab versus Bisphosphonates for Reducing Fractures in Postmenopausal Women with Osteoporosis: A Meta-Analysis.
Thal KA; Nudy M; Moser EM; Foy AJ
J Am Board Fam Med; 2023 Feb; 36(1):175-185. PubMed ID: 36653115
[TBL] [Abstract][Full Text] [Related]
20. Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy.
Silverman SL; Komm BS; Mirkin S
Maturitas; 2014 Nov; 79(3):241-7. PubMed ID: 25124532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
